Thomas Eiwegger

EAACI guidelines on the management of IgE‐mediated food allergy

From bite to brain: Neuro‐immune interactions in food allergy

Food Allergy Genetics and Epigenetics: A Review of Genome‐Wide Association Studies

<scp>EAACI</scp> guidelines on the diagnosis of <scp>IgE</scp>‐mediated food allergy

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

Pathogenesis, immunology, and immune‐targeted management of the multisystem inflammatory syndrome in children (MIS‐C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives

Establishing Amoxicillin Allergy in Children Through Direct Graded Oral Challenge (GOC): Evaluating Risk Factors for Positive Challenges, Safety, and Risk of Cross-Reactivity to Cephalosporines

EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

EAACI Biologicals Guidelines—Recommendations for severe asthma

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)

A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)

Biologicals in atopic disease in pregnancy: An EAACI position paper

Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

Toward personalization of asthma treatment according to trigger factors

EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis

Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic

Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?